MX366899B - Nuevos compuestos. - Google Patents
Nuevos compuestos.Info
- Publication number
- MX366899B MX366899B MX2014014112A MX2014014112A MX366899B MX 366899 B MX366899 B MX 366899B MX 2014014112 A MX2014014112 A MX 2014014112A MX 2014014112 A MX2014014112 A MX 2014014112A MX 366899 B MX366899 B MX 366899B
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- new compounds
- cancer
- diseases
- processes
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- -1 naphthyridine derivative compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- YEYHFKBVNARCNE-UHFFFAOYSA-N pyrido[2,3-b]pyrazine Chemical compound N1=CC=NC2=CC=CN=C21 YEYHFKBVNARCNE-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261653140P | 2012-05-30 | 2012-05-30 | |
| GBGB1209609.5A GB201209609D0 (en) | 2012-05-30 | 2012-05-30 | New compounds |
| US201361782210P | 2013-03-14 | 2013-03-14 | |
| PCT/GB2013/051428 WO2013179034A1 (en) | 2012-05-30 | 2013-05-30 | New compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014014112A MX2014014112A (es) | 2015-06-17 |
| MX366899B true MX366899B (es) | 2019-07-30 |
Family
ID=46546191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014014112A MX366899B (es) | 2012-05-30 | 2013-05-30 | Nuevos compuestos. |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9303030B2 (instruction) |
| EP (1) | EP2861584B1 (instruction) |
| JP (1) | JP6208223B2 (instruction) |
| KR (1) | KR102134204B1 (instruction) |
| CN (1) | CN104507931B (instruction) |
| AU (1) | AU2013269317B2 (instruction) |
| BR (1) | BR112014029706B1 (instruction) |
| CA (1) | CA2874911C (instruction) |
| DK (1) | DK2861584T3 (instruction) |
| ES (1) | ES2791179T3 (instruction) |
| GB (1) | GB201209609D0 (instruction) |
| HR (1) | HRP20200632T1 (instruction) |
| HU (1) | HUE049129T2 (instruction) |
| IN (1) | IN2014MN02049A (instruction) |
| LT (1) | LT2861584T (instruction) |
| MX (1) | MX366899B (instruction) |
| RU (1) | RU2654857C2 (instruction) |
| SI (1) | SI2861584T1 (instruction) |
| TW (1) | TWI602816B (instruction) |
| WO (1) | WO2013179034A1 (instruction) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201209609D0 (en) * | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| SG11201500125QA (en) | 2012-07-11 | 2015-02-27 | Blueprint Medicines Corp | Inhibitors of the fibroblast growth factor receptor |
| AR094812A1 (es) | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| DK3395814T3 (da) | 2013-10-25 | 2022-07-04 | Blueprint Medicines Corp | Hæmmere af fibroblastvækstfaktorreceptoren |
| WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| MX373150B (es) | 2014-03-26 | 2020-04-21 | Astex Therapeutics Ltd | Combinaciones de un inhibidor del factor de crecimiento de fibroblasto (fgfr) y un inhibidor del receptor del factor de crecimiento 1 similar a insulina (igf1r). |
| MA55696A (fr) | 2014-03-26 | 2022-02-23 | Astex Therapeutics Ltd | Combinaisons |
| AU2015304465B2 (en) | 2014-08-18 | 2019-05-09 | Eisai R&D Management Co., Ltd. | Salt of monocyclic pyridine derivative and crystal thereof |
| PT3198033T (pt) * | 2014-09-26 | 2022-05-25 | Janssen Pharmaceutica Nv | Utilização de painéis de genes mutantes de fgfr na identificação de pacientes com cancro que serão sensíveis ao tratamento com um inibidor de fgfr |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| WO2016152907A1 (ja) | 2015-03-25 | 2016-09-29 | 国立研究開発法人国立がん研究センター | 胆管癌治療剤 |
| US10478494B2 (en) * | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| MX378230B (es) | 2015-09-23 | 2025-03-10 | Janssen Pharmaceutica Nv | 1,4-benzodiazepinas biheteroarilo sustituidas y usos de las mismas para el tratamiento del cáncer. |
| MX382919B (es) | 2015-09-23 | 2025-03-13 | Janssen Pharmaceutica Nv | Nuevos compuestos. |
| JPWO2019189241A1 (ja) | 2018-03-28 | 2021-03-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 肝細胞癌治療剤 |
| CN111171020A (zh) * | 2018-11-13 | 2020-05-19 | 上海轶诺药业有限公司 | 一类六元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途 |
Family Cites Families (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2940972A (en) | 1957-06-27 | 1960-06-14 | Thomae Gmbh Dr K | Tri-and tetra-substituted pteridine derivatives |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| GB9125001D0 (en) | 1991-11-25 | 1992-01-22 | Ici Plc | Heterocyclic compounds |
| US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| US6331555B1 (en) | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| WO1998004689A1 (en) | 1995-07-31 | 1998-02-05 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| TW472045B (en) | 1996-09-25 | 2002-01-11 | Astra Ab | Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation |
| EA008136B1 (ru) | 1997-05-28 | 2007-04-27 | Авентис Фармасьютикалз Инк. | ХИНОЛИНОВЫЕ И ХИНОКСАЛИНОВЫЕ СОЕДИНЕНИЯ, ИНГИБИРУЮЩИЕ ТИРОЗИНКИНАЗЫ ТРОМБОЦИТАРНОГО ФАКТОРА РОСТА И/ИЛИ p56 |
| UA71555C2 (en) | 1997-10-06 | 2004-12-15 | Zentaris Gmbh | Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives |
| WO2000042026A1 (en) | 1999-01-15 | 2000-07-20 | Novo Nordisk A/S | Non-peptide glp-1 agonists |
| YU18502A (sh) | 1999-09-15 | 2004-12-31 | Warner-Lambert Company | Pteridinoni kao inhibitori kinaza |
| DE10013318A1 (de) | 2000-03-17 | 2001-09-20 | Merck Patent Gmbh | Formulierung enthaltend Chinoxalinderivate |
| WO2002076985A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| WO2003051833A2 (en) | 2001-12-18 | 2003-06-26 | Merck & Co., Inc. | Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| DK1463506T3 (da) | 2001-12-24 | 2010-01-11 | Astrazeneca Ab | Substituerede quinazolin-derivater som inhibitorer af aurora-kinaser |
| JP2003213463A (ja) | 2002-01-17 | 2003-07-30 | Sumitomo Chem Co Ltd | 金属腐食防止剤および洗浄液 |
| US7074534B2 (en) | 2002-07-10 | 2006-07-11 | E. I. Du Pont De Nemours And Company | Polymeric charge transport compositions and electronic devices made with such compositions |
| US7825132B2 (en) | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
| CA2500727A1 (en) | 2002-10-03 | 2004-04-15 | Targegen, Inc. | Vasculostatic agents and methods of use thereof |
| AR043059A1 (es) | 2002-11-12 | 2005-07-13 | Bayer Pharmaceuticals Corp | Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos |
| US7098332B2 (en) | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
| ATE433967T1 (de) | 2003-01-17 | 2009-07-15 | Warner Lambert Co | 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation |
| EP1620413A2 (en) | 2003-04-30 | 2006-02-01 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| US7244739B2 (en) | 2003-05-14 | 2007-07-17 | Torreypines Therapeutics, Inc. | Compounds and uses thereof in modulating amyloid beta |
| RU2330851C9 (ru) | 2003-05-23 | 2008-10-20 | Центарис Гмбх | ПИРИДО[2,3-b]ПИРАЗИНОВЫЕ ПРОИЗВОДНЫЕ, ЛЕКАРСТВЕННОЕ СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ ИЛИ НАРУШЕНИЯ, КОТОРЫЕ ОБУСЛОВЛЕНЫ НЕПРАВИЛЬНО НАПРАВЛЕННЫМИ ПРОЦЕССАМИ КЛЕТОЧНОЙ СИГНАЛЬНОЙ ТРАНСДУКЦИИ, СПОСОБ ПОЛУЧЕНИЯ ЛЕКАРСТВЕННОГО СРЕДСТВА |
| DE10323345A1 (de) | 2003-05-23 | 2004-12-16 | Zentaris Gmbh | Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren |
| WO2005007099A2 (en) | 2003-07-10 | 2005-01-27 | Imclone Systems Incorporated | Pkb inhibitors as anti-tumor agents |
| AU2004259000A1 (en) | 2003-07-21 | 2005-02-03 | Bethesda Pharmaceuticals, Inc. | Design and synthesis of optimized ligands for PPAR |
| PT1673092E (pt) | 2003-10-17 | 2007-11-23 | 4 Aza Ip Nv | ''derivados de pteridina substituídos com heterociclos e sua utilização em terapia'' |
| EP2762475A1 (en) | 2003-11-07 | 2014-08-06 | Novartis Vaccines and Diagnostics, Inc. | Pharmaceutically acceptable salts of quinolinone compounds and their medical use |
| BRPI0416206A (pt) | 2003-11-20 | 2006-12-26 | Janssen Pharmaceutica Nv | 2-quinolinonas e 2-quinoxalinonas substituìdas por 6-alquenila e 6-fenilalquila como inibidores de polimerase de poli(adp-ribose) |
| RU2377241C2 (ru) | 2003-11-24 | 2009-12-27 | Ф.Хоффманн-Ля Рош Аг | Производные пиразоло-имидазопиримидина, обладающие антагонистической активностью в отношении кортикотропин-рилизинг фактора (crf) |
| US8247576B2 (en) | 2003-12-23 | 2012-08-21 | Astex Therapeutics Limited | Pyrazole derivatives as protein kinase modulators |
| US7205316B2 (en) | 2004-05-12 | 2007-04-17 | Abbott Laboratories | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands |
| US7098222B2 (en) | 2004-05-12 | 2006-08-29 | Abbott Laboratories | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
| JP2008511599A (ja) | 2004-08-31 | 2008-04-17 | アストラゼネカ アクチボラグ | キナゾリノン誘導体およびＢ−Ｒａｆ阻害薬としてのそれらの使用 |
| KR100875408B1 (ko) | 2004-10-14 | 2008-12-23 | 에프. 호프만-라 로슈 아게 | Ｃｄｋ1 항증식성 활성을 갖는 1,5-나프티리딘 아졸리디논 |
| SI1830869T1 (sl) | 2004-12-24 | 2013-12-31 | Spinifex Pharmaceuticals Pty Ltd | Postopek zdravljenja ali profilakse |
| EP1848704A4 (en) | 2005-02-14 | 2011-05-11 | Bionomics Ltd | Novel tubulin polymerisation inhibitors |
| EP1853261B1 (de) | 2005-03-03 | 2017-01-11 | Universität des Saarlandes | Selektive hemmstoffe humaner corticoidsynthasen |
| CA2606017A1 (en) | 2005-05-12 | 2006-11-23 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| AU2006247315A1 (en) | 2005-05-18 | 2006-11-23 | Wyeth | 4, 6-diamino-[1,7] naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same |
| GB0513692D0 (en) | 2005-07-04 | 2005-08-10 | Karobio Ab | Novel pharmaceutical compositions |
| CA2628039A1 (en) | 2005-11-11 | 2007-05-18 | Aeterna Zentaris Gmbh | Novel pyridopyrazines and their use as modulators of kinases |
| US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
| EP1790342A1 (de) | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege |
| CA2634721C (en) | 2005-12-21 | 2014-06-17 | Janssen Pharmaceutica N.V. | Triazolopyridazines as tyrosine kinase modulators |
| EP2024342A2 (en) | 2006-05-01 | 2009-02-18 | Pfizer Products Incorporated | Substituted 2-amino-fused heterocyclic compounds |
| GB0609621D0 (en) | 2006-05-16 | 2006-06-21 | Astrazeneca Ab | Novel co-crystal |
| JP2009537590A (ja) | 2006-05-24 | 2009-10-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 四員複素環で置換された置換プテリジン |
| US20100016293A1 (en) | 2006-07-03 | 2010-01-21 | Rogier Adriaan Smits | Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use |
| JP2008127446A (ja) | 2006-11-20 | 2008-06-05 | Canon Inc | １，５−ナフチリジン化合物及び有機発光素子 |
| WO2008076278A2 (en) | 2006-12-13 | 2008-06-26 | Schering Corporation | Methods of cancer treatment with igf1r inhibitors |
| CA2673736A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| HRP20150642T1 (hr) | 2006-12-22 | 2015-08-14 | Astex Therapeutics Limited | BICIKLIÄŚKE HETEROCIKLIÄŚKE TVARI KAO INHIBITORI FGFR-a |
| CN101652352A (zh) | 2006-12-22 | 2010-02-17 | 诺瓦提斯公司 | 用于抑制pdk1的喹唑啉类 |
| KR20080062876A (ko) | 2006-12-29 | 2008-07-03 | 주식회사 대웅제약 | 신규한 항진균성 트리아졸 유도체 |
| EP1990342A1 (en) * | 2007-05-10 | 2008-11-12 | AEterna Zentaris GmbH | Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof |
| PE20090288A1 (es) | 2007-05-10 | 2009-04-03 | Smithkline Beecham Corp | Derivados de quinoxalina como inhibidores de la pi3 quinasa |
| WO2008150827A1 (en) | 2007-05-29 | 2008-12-11 | Smithkline Beecham Corporation | Naphthyridine, derivatives as p13 kinase inhibitors |
| AR066879A1 (es) | 2007-06-08 | 2009-09-16 | Novartis Ag | Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus |
| WO2008155378A1 (en) | 2007-06-21 | 2008-12-24 | Janssen Pharmaceutica Nv | Polymorphic and hydrate forms, salts and process for preparing 6-{difluoro[6-(1-methyl-1h-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline |
| WO2009019518A1 (en) | 2007-08-09 | 2009-02-12 | Astrazeneca Ab | Pyrimidine compounds having a fgfr inhibitory effect |
| WO2009021083A1 (en) | 2007-08-09 | 2009-02-12 | Smithkline Beecham Corporation | Quinoxaline derivatives as pi3 kinase inhibitors |
| US20090054304A1 (en) | 2007-08-23 | 2009-02-26 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 for treatment of disease |
| NZ585139A (en) | 2007-11-16 | 2012-05-25 | Incyte Corp | 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as jak inhibitors |
| MX2010012064A (es) | 2008-05-05 | 2010-12-06 | Schering Corp | Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer. |
| JP5351254B2 (ja) | 2008-05-23 | 2013-11-27 | ノバルティス アーゲー | キノキサリン−およびキノリン−カルボキシアミド誘導体 |
| WO2010059771A1 (en) | 2008-11-20 | 2010-05-27 | Osi Pharmaceuticals, Inc. | Substituted pyrrolo[2,3-b]-pyridines and-pyrazines |
| CN102361863B (zh) | 2009-01-21 | 2014-12-03 | 巴斯利尔药物股份公司 | 新的二环抗生素 |
| US20110288090A1 (en) | 2009-02-02 | 2011-11-24 | Armstrong Donna J | Inhibitors of AKT Activity |
| TW201041888A (en) | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| PT2440545T (pt) | 2009-06-12 | 2019-07-19 | Inst Curie | Compostos úteis para tratar cancro |
| JP5696856B2 (ja) | 2009-09-03 | 2015-04-08 | バイオエナジェニックス | Ｐａｓｋの阻害用複素環式化合物 |
| WO2011026579A1 (en) | 2009-09-04 | 2011-03-10 | Bayer Schering Pharma Aktiengesellschaft | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors |
| EP2332939A1 (en) | 2009-11-26 | 2011-06-15 | Æterna Zentaris GmbH | Novel Naphthyridine derivatives and the use thereof as kinase inhibitors |
| KR20130053404A (ko) | 2010-03-30 | 2013-05-23 | 베르선 코포레이션 | 트롬빈 억제제로서의 다중치환된 방향족 화합물 |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| US8513421B2 (en) | 2010-05-19 | 2013-08-20 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| CN103153062B (zh) | 2010-05-24 | 2015-07-15 | 因特利凯有限责任公司 | 杂环化合物及其用途 |
| GB201020179D0 (en) * | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| CN102532141A (zh) | 2010-12-08 | 2012-07-04 | 中国科学院上海药物研究所 | [1，2，4]三唑并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途 |
| US8987257B2 (en) | 2011-01-31 | 2015-03-24 | Novartis Ag | Heterocyclic derivatives |
| CA2828483A1 (en) | 2011-02-23 | 2012-11-01 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
| WO2012118492A1 (en) | 2011-03-01 | 2012-09-07 | Array Biopharma Inc. | Heterocyclic sulfonamides as raf inhibitors |
| AU2012300317B2 (en) | 2011-08-26 | 2016-12-01 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| WO2013040515A1 (en) * | 2011-09-14 | 2013-03-21 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| US9249110B2 (en) | 2011-09-21 | 2016-02-02 | Neupharma, Inc. | Substituted quinoxalines as B-raf kinase inhibitors |
| WO2013052699A2 (en) | 2011-10-04 | 2013-04-11 | Gilead Calistoga Llc | Novel quinoxaline inhibitors of pi3k |
| EA023935B1 (ru) | 2011-10-28 | 2016-07-29 | Новартис Аг | Производные пурина и их применение для лечения заболевания |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| JO3210B1 (ar) | 2011-10-28 | 2018-03-08 | Merck Sharp & Dohme | مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
| MA55696A (fr) | 2014-03-26 | 2022-02-23 | Astex Therapeutics Ltd | Combinaisons |
| MX373150B (es) | 2014-03-26 | 2020-04-21 | Astex Therapeutics Ltd | Combinaciones de un inhibidor del factor de crecimiento de fibroblasto (fgfr) y un inhibidor del receptor del factor de crecimiento 1 similar a insulina (igf1r). |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
-
2012
- 2012-05-30 GB GBGB1209609.5A patent/GB201209609D0/en not_active Ceased
-
2013
- 2013-05-21 TW TW102117905A patent/TWI602816B/zh active
- 2013-05-30 US US14/404,188 patent/US9303030B2/en active Active
- 2013-05-30 AU AU2013269317A patent/AU2013269317B2/en active Active
- 2013-05-30 JP JP2015514588A patent/JP6208223B2/ja active Active
- 2013-05-30 LT LTEP13731851.5T patent/LT2861584T/lt unknown
- 2013-05-30 RU RU2014153591A patent/RU2654857C2/ru active
- 2013-05-30 WO PCT/GB2013/051428 patent/WO2013179034A1/en active Application Filing
- 2013-05-30 EP EP13731851.5A patent/EP2861584B1/en active Active
- 2013-05-30 DK DK13731851.5T patent/DK2861584T3/da active
- 2013-05-30 CA CA2874911A patent/CA2874911C/en active Active
- 2013-05-30 HU HUE13731851A patent/HUE049129T2/hu unknown
- 2013-05-30 IN IN2049MUN2014 patent/IN2014MN02049A/en unknown
- 2013-05-30 HR HRP20200632TT patent/HRP20200632T1/hr unknown
- 2013-05-30 SI SI201331709T patent/SI2861584T1/sl unknown
- 2013-05-30 MX MX2014014112A patent/MX366899B/es active IP Right Grant
- 2013-05-30 ES ES13731851T patent/ES2791179T3/es active Active
- 2013-05-30 KR KR1020147036353A patent/KR102134204B1/ko active Active
- 2013-05-30 CN CN201380040601.9A patent/CN104507931B/zh active Active
- 2013-05-30 BR BR112014029706-1A patent/BR112014029706B1/pt active IP Right Grant
-
2016
- 2016-01-19 US US15/000,304 patent/US9737544B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX366899B (es) | Nuevos compuestos. | |
| GB201118656D0 (en) | New compounds | |
| MX349004B (es) | Nuevos compuestos. | |
| GB201209613D0 (en) | New compounds | |
| IN2014MN00986A (instruction) | ||
| IN2012MN02591A (instruction) | ||
| PH12016501139B1 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| PH12015500274B1 (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
| IN2014MN00988A (instruction) | ||
| TW201613901A (en) | New compounds | |
| TN2015000278A1 (en) | Autotaxin inhibitors | |
| PH12014501738A1 (en) | Piperidino-pyrimidine derivatives for the treatment of viral infections | |
| PH12015500713B1 (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases | |
| PH12014501991B1 (en) | Phenicol antibacterials | |
| MX2016008130A (es) | Derivados de piperidina con actividad multimodal contra el dolor. | |
| IN2014DN03010A (instruction) | ||
| IN2013MU03118A (instruction) | ||
| MX2014004742A (es) | Nuevos agentes antibacterianos de fenicol. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |